Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
Frequently asked questions
What sector does Molecure S.A. (MOC) operate in?
Molecure S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Molecure S.A. (MOC) current stock price?
As of the latest data, Molecure S.A. stock price is PLN 6.06, with a previous close of PLN 6.19. Molecure S.A. lost -PLN 0.13 in the last trading session, representing a -2.1% loss.
What is Molecure S.A. (MOC) current market capitalization?
Molecure S.A. market cap is approximately 149.83 million.
What is Molecure S.A. (MOC) Earnings Per Share (EPS)?
The trailing EPS is -PLN 0.99.
What is Molecure S.A. (MOC) EBITDA?
Molecure S.A. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.52 million.
Does Molecure S.A. (MOC) pay dividends?
No. Molecure S.A. does not pay a dividend.
What is Molecure S.A. (MOC) beta (volatility) score?
Molecure S.A. has a beta of 1.001, meaning its volatility is roughly in line with the market.
